使用基于模型的元分析开发联合口服避孕药的突破性出血模型
Huili Chen1, Dain Chun1, Karthik Lingineni1,2
1Department of Pharmaceutics, College of Pharmacy, Center for Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, Florida, USA.
CPT: pharmacometrics & systems pharmacology
|November 17, 2024
概括
使用联合口服避孕药 (COCs) 的突破性出血 (BTB) 最初会增加,但随着时间的推移会恢复到基线. 较高的乙乙二醇 (EE) 剂量加快了这种回归,有助于COC的坚持.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生殖健康 生殖健康
- 临床药房 临床药房
背景情况:
- 突破性出血 (BTB) 是荷尔蒙避孕药的常见副作用之一.
- 了解BTB与联合口服避孕药 (COC) 剂量之间的关系对于遵守至关重要.
- 对于BTB的孕激素/乙inyl Estradiol (EE) 剂量反应现有数据是有限的.
研究的目的:
- 为了确定使用BTB作为药理动力学终点的COCs的剂量反应关系.
- 在各种孕激素/EE组合中分析BTB模式.
- 为了告知最佳的COC疗法选择.
主要方法:
- 进行了基于模型的元分析 (MBMA).
- 分析了25项BTB研究的数据.
- 评估了四种孕激素 (脱凝,多司匹伦,gestodene,levonorgestrel) 与不同剂量的EE结合使用.
主要成果:
- 在COC启动时,BTB显著增加,但随着时间的推移而下降.
- BTB正常化的时间取决于EE剂量.
- 在30微克EE时,BTB在3个月内恢复到基线,但在15-20微克EE时,不管孕激素.
结论:
- 已建立的BTB剂量-反应关系可以指导最佳的COC选择.
- 研究结果为评估BTB.的药物相互作用和人口统计等因素提供了基础.
- EE剂量是COC使用期间BTB解决的关键决定因素.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121
Pharmacokinetic Models: Overview
592
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
592
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
471
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
471
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


